GLSI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 16:00):

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers...

Stats
Today's Volume	33 765.00
Average Volume	53 890.00
Market Cap	180.43M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.200 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.30
ATR14	$0.0940 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Snehal	Buy	3 000	Common Stock
2024-03-22	Patel Snehal	Buy	2 500	Common Stock
2024-03-20	Patel Snehal	Buy	1 500	Common Stock
2024-03-05	Patel Snehal	Buy	30 500	Common Stock
2024-03-04	Patel Snehal	Buy	4 100	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 968 139 \| Sell: 271 338

Volume Correlation

Long: -0.21 (neutral)

Short: -0.40 (neutral)

Signal:(42.829) Neutral

Greenwich LifeSciences, Correlation

10 Most Positive Correlations
LNW	0.936
ICLR	0.932
SOUN	0.917
FEMY	0.914
ARQQ	0.912
CELH	0.91
NOTV	0.909
BLCN	0.9
MTRX	0.898
HAPP	0.897

10 Most Negative Correlations
DCRC	-0.882
SABR	-0.874
METX	-0.867
GMII	-0.862
ASRVP	-0.855
CFV	-0.843
XEL	-0.841
MFIN	-0.822
CYAN	-0.821
TWKS	-0.82

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Greenwich LifeSciences, Correlation - Currency/Commodity

-0.02
( neutral )

-0.05
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.18
( neutral )

0.07
( neutral )

Greenwich LifeSciences, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2023
Revenue:	$0
Gross Profit:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2022
Revenue:	$0
Gross Profit:	$-3 612.00 (0.00 %)
EPS:	$-0.590

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Greenwich LifeSciences,

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.